Watson, Sandoz settle Medicaid whistleblower suits for $145M

Watson Pharmaceuticals ($WPI) and Novartis' ($NVS) generics unit Sandoz have agreed to settle False Claims Act lawsuits alleging  they overstated the prices on drugs sold to Medicaid programs. Watson agreed to pay $79 million, and Sandoz will cough up $66 million. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.